Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.

Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer

NCT04128800 ·Status: UNKNOWN ·Phase: PHASE2

Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma

NCT03376737 ·Status: UNKNOWN ·Phase: PHASE2

Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy

NCT02711007 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)

NCT03416231 ·Status: UNKNOWN ·Phase: PHASE2

Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)

NCT02995187 ·Status: UNKNOWN ·Phase: PHASE2

Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study

NCT03594682 ·Status: UNKNOWN ·Phase: NA

Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC

NCT03411967 ·Status: UNKNOWN ·Phase: PHASE2

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

NCT03180476 ·Status: COMPLETED ·Phase: PHASE2

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

NCT03201146 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

NCT03050411 ·Status: UNKNOWN ·Phase: PHASE1

Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)

NCT05277480 ·Status: COMPLETED ·Phase: PHASE2

The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)

NCT03811054 ·Status: UNKNOWN ·Phase: PHASE2

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

NCT06709859 ·Status: RECRUITING ·Phase: PHASE2

The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

NCT02493582 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

NCT04133337 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer

NCT03129256 ·Status: COMPLETED ·Phase: PHASE2

A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

NCT01270386 ·Status: COMPLETED ·Phase: PHASE2

Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC

NCT02852798 ·Status: UNKNOWN

Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer

NCT03651219 ·Status: UNKNOWN ·Phase: PHASE3

Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma

NCT03130270 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer

NCT03100955 ·Status: UNKNOWN ·Phase: PHASE3

Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)

NCT02332512 ·Status: UNKNOWN ·Phase: PHASE3

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

NCT03389256 ·Status: UNKNOWN ·Phase: PHASE2

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

NCT04201756 ·Status: COMPLETED ·Phase: PHASE2

The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer

NCT02515435 ·Status: UNKNOWN ·Phase: PHASE2